Human IL-1RA Protein, Tag Free (MALS verified)

製品番号/仕様
価格
Availability
数量
ILA-H5119-100ug
$310.00
In Stock - Delivery in 1-2 business days
ILA-H5119-1mg (500ug X 2)
$2,245.00
In Stock - Delivery in 2 weeks
ILA-H5119
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3, IL1F3, IL1RA, IRAP, MVCD4

Source

Human IL-1RA Protein, Tag Free (ILA-H5119) is expressed from E. coli cells. It contains AA Arg 26 - Glu 177 (Accession # P18510-1).

Predicted N-terminus: Met

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 17.3 kDa. The protein migrates as 15-16 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

バックグランド

Interleukin-1 receptor antagonist (IL-1RA) is a naturally occurring anti-inflammatory antagonist of interleukin-1 family of pro-inflammatory cytokines. It competes with IL-1α and IL-1β to bind IL-1R1, thereby acting as an endogenous inhibitor of the IL-1 signaling pathway. IL‐1RA has been connected with a variety of diseases, including cardiovascular disease, type II diabetes, carcinoma, and joint diseases.